Antiphospholipid antibodies (aPL) are associated with a clear but variable risk for thromboses at multiple vascular sites and with a wide spectrum of clinical features comprising both the primary and secondary antiphospholipid antibody syndromes (APS). The recent literature reviewed here includes refined and more quantitative descriptions of aPL-associated clinical phenomena and APS features in studies of increasingly larger patient cohorts, and better understanding of the heterogeneity of aPL relative to binding dependency on beta;2glycoprotein I and other phospholipids. There is expanded knowledge of pathogenesis of aPL fromin vitroandin vivostudies in murine and human models and intriguing data on therapeutic modalities, old and new.
展开▼
